Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novabay Pharmaceuticals (NY: NBY )

0.6942 -0.0048 (-0.69%)
Official Closing Price Updated: 8:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novabay Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 Next >
NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Rise and shine! We're gearing up for another busy day of trading with a breakdown of the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
26 Stocks Moving in Thursday's Pre-Market Session
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) rose 31.9% to $3.35 in pre-market trading after jumping around 25% on Wednesday. Clarus Therapeutics Holdings, Inc. (NASDAQ:... 
Via Benzinga
23 Stocks Moving in Tuesday's Pre-Market Session
Gainers ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss. Sharps Technology, Inc. (NASDAQ: STSS... 
Via Benzinga
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to QVC® to Discuss DERMAdoctor’s Eczema Treatment
From NovaBay Pharmaceuticals, Inc
Via Business Wire
NovaBay Pharmaceuticals Introduces Hydrating Cleansing Oil to its DERMAdoctor Calm Cool + Corrected Product Line
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals's Return On Capital Employed Insights
According to Benzinga Pro data, during Q4, NovaBay Pharmaceuticals (AMEX:NBY) posted sales of $2.64 million. Earnings were up 93.1%, but NovaBay Pharmaceuticals still reported an overall loss of... 
Via Benzinga
NovaBay Pharmaceuticals Reports 2021 Fourth Quarter and Full Year Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For March 29, 2022
Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million. 
Via Benzinga
NovaBay Pharmaceuticals Earnings Preview
NovaBay Pharmaceuticals (AMEX:NBY) is set to give its latest quarterly earnings report on Tuesday, 2022-03-29. Here's what investors need to know before the announcement. Analysts estimate that NovaBay... 
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
NovaBay Pharmaceuticals to Hold 2021 Fourth Quarter and Full Year Conference Call on March 29
From NovaBay® Pharmaceuticals, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, trader! Let's start off the final day of the workweek right with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
25 Stocks Moving in Friday's Pre-Market Session
Gainers Grom Social Enterprises, Inc. (NASDAQ: GROM) rose 60.5% to $1.53 in pre-market trading. StoneCo Ltd. (NASDAQ: STNE) shares rose 23.7% to $11.90 in pre-market trading... 
Via Benzinga
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Present DERMAdoctor Eczema Treatment as QVC® On-Air Guest
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in China
From NovaBay Pharmaceuticals, Inc
Via Business Wire
NovaBay Pharmaceuticals Announces Changes to Its Board of Directors
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Donate 2.5 Million KN95 Masks
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Expands Its Eyecare Product Portfolio With the Launch of Lubricating Eye Drops for the Immediate Relief of Dry Eye Symptoms
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Holds Special Meeting of Stockholders
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
DERMAdoctor’s Calm Cool + Corrected Eczema Balm Receives National Eczema Association Seal of Acceptance
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Reports Third Quarter 2021 Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Closes DERMAdoctor Acquisition
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Closes $15.0 Million Private Placement
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Announces Pricing of $15.0 Million Private Placement
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Earnings Perspective: Return On Capital Employed
Benzinga Pro data, NovaBay Pharmaceuticals (AMEX:NBY) reported Q2 sales of $2.13 million. Earnings fell to a loss of $1.86 million, resulting in a 22.3% decrease from last... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.